Antibody therapy of cancer
- PMID:22437872
- DOI: 10.1038/nrc3236
Antibody therapy of cancer
Abstract
The use of monoclonal antibodies (mAbs) for cancer therapy has achieved considerable success in recent years. Antibody-drug conjugates are powerful new treatment options for lymphomas and solid tumours, and immunomodulatory antibodies have also recently achieved remarkable clinical success. The development of therapeutic antibodies requires a deep understanding of cancer serology, protein-engineering techniques, mechanisms of action and resistance, and the interplay between the immune system and cancer cells. This Review outlines the fundamental strategies that are required to develop antibody therapies for cancer patients through iterative approaches to target and antibody selection, extending from preclinical studies to human trials.
Trial registration: ClinicalTrials.govNCT00829166NCT01120184.
Similar articles
- [An overview of antibody-based cancer therapy].Miao QF, Shao RG, Zhen YS.Miao QF, et al.Yao Xue Xue Bao. 2012 Oct;47(10):1261-8.Yao Xue Xue Bao. 2012.PMID:23289136Review.Chinese.
- Antibody-targeted drugs and drug resistance--challenges and solutions.Shefet-Carasso L, Benhar I.Shefet-Carasso L, et al.Drug Resist Updat. 2015 Jan;18:36-46. doi: 10.1016/j.drup.2014.11.001. Epub 2014 Nov 21.Drug Resist Updat. 2015.PMID:25476546Review.
- Are targeted therapies really targeted?Schilsky RL.Schilsky RL.Clin Adv Hematol Oncol. 2003 Dec;1(12):722-3.Clin Adv Hematol Oncol. 2003.PMID:16258475No abstract available.
- Antibody-drug conjugates: Promising and efficient tools for targeted cancer therapy.Nasiri H, Valedkarimi Z, Aghebati-Maleki L, Majidi J.Nasiri H, et al.J Cell Physiol. 2018 Sep;233(9):6441-6457. doi: 10.1002/jcp.26435. Epub 2018 Mar 25.J Cell Physiol. 2018.PMID:29319167Review.
- Using the Lessons Learned From the Clinic to Improve the Preclinical Development of Antibody Drug Conjugates.Jackson D, Stover D.Jackson D, et al.Pharm Res. 2015 Nov;32(11):3458-69. doi: 10.1007/s11095-014-1536-7. Epub 2014 Oct 23.Pharm Res. 2015.PMID:25339341Free PMC article.Review.
Cited by
- Recruiting Immunity for the Fight against Colorectal Cancer: Current Status and Challenges.Al-Hujaily EM, Al-Sowayan BS, Alyousef Z, Uddin S, Alammari F.Al-Hujaily EM, et al.Int J Mol Sci. 2022 Nov 8;23(22):13696. doi: 10.3390/ijms232213696.Int J Mol Sci. 2022.PMID:36430176Free PMC article.Review.
- Harnessing and Enhancing Macrophage Phagocytosis for Cancer Therapy.Chen S, Lai SWT, Brown CE, Feng M.Chen S, et al.Front Immunol. 2021 Mar 10;12:635173. doi: 10.3389/fimmu.2021.635173. eCollection 2021.Front Immunol. 2021.PMID:33790906Free PMC article.Review.
- The new pig on the block: modelling cancer in pigs.Flisikowska T, Kind A, Schnieke A.Flisikowska T, et al.Transgenic Res. 2013 Aug;22(4):673-80. doi: 10.1007/s11248-013-9720-9. Epub 2013 Jun 8.Transgenic Res. 2013.PMID:23748932Review.
- Insulin-like growth factor system in cancer: novel targeted therapies.Brahmkhatri VP, Prasanna C, Atreya HS.Brahmkhatri VP, et al.Biomed Res Int. 2015;2015:538019. doi: 10.1155/2015/538019. Epub 2015 Mar 19.Biomed Res Int. 2015.PMID:25866791Free PMC article.Review.
- Epithelial Ovarian Cancer and the Immune System: Biology, Interactions, Challenges and Potential Advances for Immunotherapy.Macpherson AM, Barry SC, Ricciardelli C, Oehler MK.Macpherson AM, et al.J Clin Med. 2020 Sep 14;9(9):2967. doi: 10.3390/jcm9092967.J Clin Med. 2020.PMID:32937961Free PMC article.Review.
References
Publication types
MeSH terms
Substances
Associated data
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources